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1 Suppression of interleukin-8 and myeloperoxidase production in the cerebrovascular bed during repeated deep
hypothermic circulatory arrest
E Kuzumi*†, A Vuylsteke*, A Downie†, JJ Dunning*, K McNeil* and DK Menon†
*Papworth Hospital, Cambridge, UK and †University of Cambridge, UK
Introduction: It has been suggested that mild hypothermia during
cardiopulmonary bypass (CPB) may attenuate, but not completely
suppress, the production of interleukin-8 (IL-8) in the brain [1]. This
study examined the effect of repeated deep hypothermic circula-
tory arrest (DHCA) on production of IL-8 and myeloperoxidase
(MPO) in the cerebrovascular bed in patients undergoing pul-
monary thromboendarterectomy (PTE).
Methods: After LREC approval and written informed consent, we
studied eight patients undergoing PTE. Anaesthetic and surgical
technique were strictly standardized [2] and all patients had a
jugular bulb catheter inserted after induction. After initiation of
CPB, all patients were cooled to below 20°C and underwent at
least two periods of DHCA for 20 min. Each DHCA period was
separated by a 10-min reperfusion interval. The levels of IL-8 and
MPO were measured in paired arterial and jugular samples drawn
simultaneously at specific time points, using enzyme-linked
immunoassay kits. Juguloarterial (j–a) gradients were then calcu-
lated. All data are expressed as median (interquartile range) and
were compared with the baseline values using the Wilcoxon
signed rank sum test. J–a gradients were compared with zero
using one-sample t-test.
Results: The baseline arterial values before CPB [T1] for IL-8 and
MPO were 12.9 (11.5–21.4) pg/ml and 4.5 (3.1–6.6) ng/ml,
respectively (Fig. 1). For both IL-8 and MPO, arterial levels signifi-
cantly increased before the first DHCA [T3] to 28.3
(21.6–43.1) pg/ml and 31.2 (26.1–11.7) ng/ml, respectively, and
remained elevated until 8 min following the second DHCA [T7].
However, no significant j–a differences for IL-8 and MPO were
found throughout this period.
Conclusions:  These data imply that the cerebral activation of
inflammatory processes represented as specific IL-8 and MPO
production in the cerebrovascular bed are suppressed during
repeated DHCA in the present study.
References
1. Nandate K, Vuylsteke A, Crosbie AE, et al: Anesth Analg 1999,
89:823–828.
2. Wilson WC, Vuylsteke A: Anaesthesia for Pulmonary
Endarterectomy. In  Thoracic Anaesthesia. Edited by Ghosh S,
Latimer RD. Oxford: Butterworth & Heinemann; 1999:223–234.
Figure 1
IL-8 and MPO concentration during DHCA. T1, postinduction; 
T2, CPB started; T3, 2 min preDHCA1; T4, 1 min postDHCA1; 
T5, 8 min postDHCA1; T6, 1 min postDHCA2; T7, 8 min postDHCA2.
*P < 0.05 versus baseline.Available online http://ccforum.com/supplements/5/SC
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2 The effect of an infusion of esmolol on the incidence of myocardial ischaemia during tracheal extubation following
coronary artery surgery
SM Kurian, R Evans, NO Fernandes and KM Sherry
Northern General Hospital NHS Trust, Sheffield, UK
Introduction: Silent myocardial ischaemia (SMI) has been shown
to be temporally associated with tracheal extubation in up to 27%
of patients after coronary artery bypass operations [1]. Patients
who develop SMI during tracheal extubation are more likely to have
a higher heart rate [1,2] and arterial pressure [2]. The aim of this
study was to determine whether an esmolol infusion could affect
the incidence of SMI during the weaning from intermittent positive
pressure ventilation and tracheal extubation following coronary
artery surgery. Patient haemodynamics and adverse events were
also assessed.
Methods: Ethics Committee Approval and informed consent were
obtained. The study was conducted in the intensive care unit (ICU)
on patients who had undergone elective coronary artery surgery.
Preoperative exclusion criteria were: digoxin therapy, electrocardio-
graphic (ECG) evidence of left ventricular hypertrophy or left
bundle branch block, cardiac pacemaker, asthma, a previous intol-
erance to beta adrenergic blockade or renal impairment. Postoper-
ative exclusion criteria were first degree heart block or beta
adrenergic agonist infusion at the time of study entry. Thirty-eight
patients were randomized to the control group (group C) and 34 to
receive a sliding scale infusion of esmolol (group E) with a target
heart rate between 55–75 bpm. The study period extended from
120 min before until 180 min after tracheal extubation. Myocardial
ischaemia, reversible ST segment depression ³2 mm or elevation
³3 mm for more than 60 s was detected using the Compas com-
puterized ambulatory ECG system (S-pace Medical, Sheffield, UK).
Heart rate and arterial pressure were recorded at 10-min intervals.
A P value < 0.05 was considered significant.
Results: One patient from each group was withdrawn because of
ECG lead faults. Two patients from group E were withdrawn
because of hypotension. The patient characteristics were compara-
ble between the two groups. The esmolol group had a lower inci-
dence of myocardial ischaemia compared with the control group
(3/31 versus 12/37; c2 analysis, P = 0.05). Heart rate increased in
group C (analysis of variance, P = 0.002) and was unchanged in
group E. Arterial pressure in both groups showed increases during
tracheal extubation. Four patients from group E had a high heart rate
that was difficult to control and a further three patients developed
hypotension.
Conclusions: Esmolol does reduce the incidence of myocardial
ischaemia in association with tracheal extubation following coro-
nary artery surgery. However, the high incidence of adverse events
limits its use in this patient population.
References
1. Barham NJ, Boomers OW, Sherry KM, Locke TJ: Myocardial
ischaemia during tracheal extubation after cardiac surgery: an
observational study. Br J Anaesth 1998, 80:832–833.
2. Conti J, Smith D: Haemodynamic responses to extubation
after cardiac surgery with and without continued sedation. Br
J Anaesth 1998, 80:834–836.
3 Beating heart coronary surgery and renal function: a prospective randomised study
ATM Tang*, R Thomas, J Knott, J Nanson, SK Ohri* and D Smith
Departments of Anaesthesia and *Cardiac Surgery, Southampton General Hospital, Southampton, UK
Introduction: Cardiopulmonary bypass (CPB) is widely regarded
as an important contributor to renal failure, a well recognised com-
plication, following coronary artery surgery (CABG). Off-pump
coronary surgery (OPCAB) is intuitively considered renoprotective.
We examine the extent of renal glomerular and tubular injury in low-
risk patients undergoing either OPCAB or on-pump coronary artery
bypass (ONCAB).
Methods: Forty patients awaiting elective CABG were prospec-
tively randomized into those undergoing OPCAB (n = 20) and
ONCAB (n = 20). Table 1 illustrates the exclusion criteria.
Glomerular and tubular injury were assessed, respectively, by
urinary excretion of microalbumin and retinol binding protein (RBP)
indexed to urinary creatinine [1]. Daily measurements were made
from admission to postoperative day 5. Fluid balance, serum creati-
nine and blood urea were also monitored.
Results: No mortality or renal complication was observed. Both
groups had similar demographic make-up. The OPCAB group
received fewer coronary grafts than their counterparts (1.8 versus
2.8; P = 0.002). Serum creatinine and blood urea remained normal
in both groups throughout the study. A dramatic and similar rise in
mean ± 2SD urinary RBP:creatinine ratio occurred in both groups
peaking on day 1 (3183 ± 2534 versus 4035 ± 4078; P = 0.43)
before returning to baseline levels. These trends were also
observed with the urinary microalbumin:creatinine ratio
(5.05 ± 2.66 versus 6.77 ± 5.76; P = 0.22). ONCAB patients had
Table 1
Exclusion criteria
Pre-existing renal disease Age above 80 years
Serum creatinine above 135 mmol/L Unstable angina
LV ejection fraction less than 40% Regular usage of nephrotoxic 
agents
Chronic or uncontrolled hypertension Perioperative inotrope 
dependency
Diabetes mellitusa significantly more negative fluid balance on postoperative day 2
(–183 ± 1118 versus 637 ± 847 ml; P < 0.05).
Conclusions: Although renal dysfunction did not clinically occur in
any patient, sensitive indicators revealed significant and similar
injury to both renal tubules and glomeruli following either OPCAB
or ONCAB. These suggest that avoidance of CPB per se does not
offer additional renoprotection to patients at low risk of periopera-
tive renal insult during CABG.
Reference
1. Tang A, El-Gamel A, Keevil B, Yonan N, Deiraniya A: The effect of
‘renal-dose’ dopamine on renal tubular function following
cardiac surgery: assessed by measuring urinary retinol
binding protein. Eur J Cardiothorac Surg 1999, 15:717–722.
4 What is the optimal paddle force for defibrillation?
CD Deakin, DM Sado, GW Petley and F Clewlow
Departments of Anaesthetics and Medical Physics and Bioengineering, Southampton General Hospital, Southampton, UK
Introduction: Firm paddle pressure during defibrillation is impor-
tant to minimize transthoracic impedance (TTI) and optimize trans-
myocardial current. Previous European Resuscitation Council
(ERC) guidelines recommended that 12 kg force should be used
[1] and the more recent International Liaison Committee on Resus-
citation (ILCOR) guidelines recommend ‘firm’ pressure [2]. The
actual relationship between force and transthoracic impedance has
not been established.
Methods: 55 patients (36 male, 19 female) undergoing general
anaesthesia for cardiac surgery were investigated. Male chests
were shaved. A pair of gel pads and paddles were placed in the
anterior–apical position according to the ILCOR guidelines. The
endotracheal tube was opened to air and paddles instrumented
with force sensors were applied to the chest wall with progressive
force to a maximum of 12 kgf. The resultant TTI was recorded at
10 measurements per second to a hard drive.
Results: Light pressure results in a high TTI that rapidly decreases
as paddle force increases (Fig. 1). An 18.7% fall in overall TTI
occurs when applying force from 0.5 to 6.0 kg. Increasing paddle
force from 6 to 12 kg results in a further decrease in TTI of 3.2%.
Conclusion: A minimum of 6 kg force applied to each paddle is
necessary to achieve 83% of the overall decrease in TTI seen at
12 kgf. Further decrease in TTI as force is applied in excess of
6 kgf is small and a force of 12 kgf only reduces TTI by a further
3.2% compared with TTI at 6 kgf. The additional clinical benefit of
applying 12 kgf as opposed to 6 kgf is questionable.
References
1. Robertson C et al: Resuscitation 1998, 37:81–90.
2. Deakin C, Petley G, Cardan E, Clewlow F: Does paddle force
applied during defibrillation meet advanced life support
guidelines of the European Resuscitation Council? Resuscita-
tion 2001, 48:301–303.
Figure 1
The relationship between force and mean TTI for 55 patients.
5 Does a remifentanil bolus attenuate the haemodynamic response to rigid bronchoscopy?
NM Agnew, CNH Tan, NDA Scawn, SH Pennefather and GN Russell
The Cardiothoracic Centre, Liverpool NHS Trust, Liverpool, UK
Introduction: The pressor response to rigid bronchoscopy result-
ing in tachycardia and hypertension is well recognized. Patients
undergoing this procedure are often elderly and many have coexist-
ing cardiovascular impairment. Haemodynamic stability is therefore
crucial. Propofol alone causes an initial drop in blood pressure,
which then rises above control levels after intubation with a signifi-
cant rise in the patients’ heart rate. Several studies have shown
that a remifentanil bolus attenuates the pressor response to intuba-
tion. The rapid recovery afforded by remifentanil is ideal for day-
case bronchoscopies. The aim of this prospective, double-blind,
randomized, controlled trial was to assess the efficacy of a remifen-
tanil bolus given before propofol in attenuating the haemodynamic
responses to rigid bronchoscopy.
Methods:  Eighty patients were randomly assigned to receive a
bolus of one of four drugs: remifentanil 1 mg/kg, remifentanil
2 mg/kg, alfentanil 10 mg/kg or saline (control). The anaesthetist
was blinded to the solution used. Anaesthesia was then induced
with a target controlled infusion (TCU) of propofol, and suxametho-
nium (1.5 mg/kg) was used as relaxant. Heart rate and noninvasive
arterial pressures were recorded at minute intervals throughout the
procedure. Repeated measures analysis of variance and area
under curve analysis were used. Power analysis required 20
patients in each group to achieve a power of 0.9 and significance
of P < 0.05.
Results:  Patient characteristics were similar. The TCI propofol
requirement was significantly higher in the saline group
Critical Care    August 2001 Vol 5 Suppl C   Selected abstracts of the 18th Spring Meeting of the Association of Cardiothoracic Anaesthetistsr
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(P = 0.0018). Changes in heart rate and arterial pressure were sig-
nificantly higher in the saline group (P = 0.0075 and P < 0.0001,
respectively; Fig. 1). No clinically significant difference was seen
between the opioids. No patients complained of nausea and there
were no differences in time to return of spontaneous ventilation,
wake up times or use of rescue vasopressors.
Conclusion: An opioid bolus significantly attenuates the haemody-
namic response to rigid bronchoscopy without delaying recovery.
However, remifentanil, in a dose of either 1 mg/kg or 2 mg/kg, was
not clinically superior to alfentanil 10 mg/kg.
Figure 1
Mean (SE) changes in heart rate from baseline during rigid bronchoscopy.
6 The effect on coagulation parameters of the transfusion of cell saved blood after cardiac surgery
V Bates, JMT Pierce, RS Gill and D O’Shaughnessy
Southampton General Hospital, Southampton, UK
Introduction: Intraoperative cell salvage (IOCS) minimizes expo-
sure to donor blood. However, the process removes plasma and
platelets and may worsen the coagulopathy induced by hepariniza-
tion and cardiopulmonary bypass (CPB). Accordingly, we under-
took a prospective observational study to examine the changes in
coagulation parameters following the retransfusion of IOCS blood.
Methods: Following Regional Ethical Committee approval and written
informed patient consent, 50 patients undergoing elective cardiac
Table 1
Coagulation data
T1 T2 T3 p T1 versus T2 p T2 versus T3 p T1 versus T3
Hb (g/l) 125 (14.6) 91.5 (12.8) 112.8 (15.5) < 0.0001 < 0.0001 < 0.0001
INR 1.1 (1.1–1.2) 1.7 (1.6–1.8) 1.5 (1.4–1.7) < 0.0001 < 0.0001 < 0.0001
APTTR 1.1 (1.0–1.2) 1.33 (1.23–1.47) 1.26 (1.18–1.34) 0.001 0.010 0.005
Factor VII (U) 99 (21.6) 67 (17) 72 (20) < 0.0001 0.0046 < 0.0001
Factor IX (U) 124 (107–136) 114 (107–132) 112 (101–127) 0.90 0.21 0.12
Fibrinogen (g/l) 3 (2.8–3.5) 2.1 (1.9–2.6) 2.2 (1.8–2.5) < 0.0001 0.7 <0.0001
Platelet count (109/l) 178 (48) 110 (40) 128 (39) < 0.0001 < 0.0001 < 0.0001
TEG MA (mm) 68 (66–70) 63 (60.5–68) 61 (59–63.5) < 0.0001 0.011 < 0.0001
Antithrombin (U) 87 (83–93) 61 (10.9) 62 (11.7) < 0.0001 0.57 < 0.0001
Activated protein C (U) 89.6 (17) 53 (12) 57 (13) < 0.0001 0.009 < 0.0001
Albumin (g/l) 33 (30–33) 22 (21–23) 22.6 (3.7) < 0.0001 0.548 < 0.0001
Calcium (mmol/l) 1.18 (1.16–1.2) 1.18 (1.15–1.9) 1.14 (0.06) 0.2639 0.0005 0.0007
Results are presented as means (SD) for normally distributed data and median (95%CI) for skewed data. Hb, haemoglobin; INR, international
normalized ratio; APTTR, activated partial thromboplastin time ratio; TEG MA, thromboelastogram maximum amplitude.
Available online http://ccforum.com/supplements/5/SCsurgery were recruited. Cardiac anaesthesia, surgery and perfusion
were conducted according to institutional protocols. CPB incorpo-
rated a Dideco D 903 oxygenator (Dideco S.p.A., Modena, Italy) with
integral heat exchanger primed with 2 l Hartmann’s solution. IOCS
was performed with a Dideco Compact Advanced Cell Saver. All
shed mediastinal blood prior to heparinization and following protamine
reversal was salvaged in addition to the CPB residue after the termi-
nation of CPB. Blood samples were drawn prior to incision (T1),
5 min after protamine reversal of heparin (T2) and 15 min after
retransfusion of IOCS blood (T3), and analysed for ionised calcium,
albumin, international normalized ratio, activated partial thromboplastin
time ratio, factors VII and IX, fibrinogen, antithrombin, activated protein
C, platelet count, haemoglobin, packed cell volume (PCV) and throm-
boelastogram. IOCS blood was analysed in five patients. Statistical
analysis used the appropriate parametric and nonparametric tests.
Significance was taken at the 5% level.
Results: Nine patients were given intraoperative blood or blood
products and were excluded from further analysis. Of the remaining
41 patients (mean age 64.6 years and mean weight 84 kg), 35 were
male. Mean CPB was 74 min and mean cross clamp was 46 min.
The median volume of IOCS was 613 ml (7.3 ml/kg). There were
almost undetectable amounts of coagulation factors present in
IOCS blood. Table 1 presents the coagulation data.
Conclusions: IOCS blood in routine cardiac surgical practice
raises the PCV to a point at which red cell transfusion is not neces-
sary. There are no deleterious effects on coagulation. We recom-
mend its routine use. To minimize unnecessary exposure to blood
products, where transfusion is protocol driven, coagulation studies
should follow IOCS blood transfusion.
Acknowledgement: This work was supported by a Haematology
Educational Grant. There were no conflicts of interest.
7 A randomized, controlled trial of blood conservation technologies in elective coronary artery bypass surgery
NA McGill, D O’Shaughnessy, MJ Herbertson and RS Gill
Shackleton Department of Anaesthesia, Southampton General Hospital, Southampton, UK
Objectives:  To assess the effectiveness of two mechanical
methods of blood conservation in reducing the exposure to transfu-
sion of allogenic red blood cells or any blood products during elec-
tive coronary artery bypass (CAB) surgery.
Introduction: The reduction of allogenic blood transfusion is a
national priority. Acute Normovolaemic Haemodilution (ANH) and
Intraoperative Cell Salvage (ICS) are two mechanical strategies
used to achieve this. A recent meta-analysis of effectiveness of ICS
[1] found no trials in cardiac surgery that employed these devices
intraoperatively. ANH trials in cardiac surgery have been equivocal
as to their benefit [2].
Methods: After local ethical approval and informed consent, 252
patients for routine CAB surgery were randomised into either a
control group (who received a standard cardiac anaesthetic and
operation), or an ICS group (where an ICS device was used during
the operation and the residual circuit volume washed), or an ANH
group (where 10 ml/kg of blood was extracted post induction and
replaced with colloid, in addition to the use of an ICS device used
as above). Outcome measures were proportions of patients
exposed to allogenic blood or blood products and total units used.
Standard transfusion thresholds were employed. Data was
analysed using a non-parametric ANOVA.
Results: There were no significant differences between the three
groups with respect to age, weight, Parsonnet score, bypass and
cross-clamp times. Hospital length of stay, and median and total
mediastinal drainage were similar across groups. Outcome mea-
sures (exposures, units of blood and P values) are shown in Table 1.
Conclusions: In elective CAB surgery, ICS significantly reduces
the risk of exposure to allogenic blood and blood products. ANH
does not confer any additional benefit.
References
1. Huet C, Salmi LR, Fergusson D, Koopman-van Gemert AWMM,
Rubens F, Laupacis A: A meta-analysis of the effectiveness of
cell salvage to minimize perioperative allogenic blood trans-
fusion in cardiac and orthopedic surgery. Anesth Analg 1999,
89:861–869.
2. Bryson GL, Laupacis A, Wells GA: Does acute normovolaemic
haemodilution reduce perioperative allogenic transfusion? A
meta-analysis. Anesth Analg 1998, 86:9–15
Table 1
Outcome measures
Control ICS P value
Exposure to blood 51% 31% 0.015 (OR 0.43, 95% CI 0.23–0.80)
Exposure to any product 56% 38% 0.030 (OR 0.47, 95% CI 0.25–0.89)
Units of blood used 1.07 (0–8) 0.68 (0–11) 0.015
ANH ICS
Exposure to blood 35% 31% NS
Exposure to any product 39% 38% NS
Units of blood used 0.63 (0–8) 0.68 (0–11) NS
OR, odds ratio; CI, confidence interval. Units of blood are shown as median (min–max).
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Table 1
Crystalloid solution mass (mg/membrane*) Diluted blood mass (mg/membrane*)
Membrane (surface area) Time (min) 28°C 37°C 28°C 37°C
SM-35 (3.5 m2) 120 113.4 ± 2.80 121.1 ± 5.60 21.35 ± 1.82 29.40 ± 3.04
CML (3.0 m2) 120 6.30 ± 1.80 25.5 ± 1.20 1.20 ± 0.09 0.90 ± 0.03
SAFE II (2.0m2) 120 23.60 ± 1.00 22.80 ± 1.00 2.60 ± 0.12 2.80 ± 0.06
*Mean ± SD mass of propofol which could be bound by membrane of intact oxygenator, n = 5 (based on mass of propofol bound per cm2 of
membrane)
8 In vitro variability in propofol absorption by different membrane oxygenators
S Hickey, I Quasim and JD Gaylor*
Department of Anaesthesia, Glasgow Royal Infirmary, Glasgow and *Department of Bioengineering, University of Strathclyde, Glasgow, UK
Introduction: The sequestration of drugs, such as fentanyl [1,2],
thiopental, nitroglycerine and propofol [3] in the extracorporeal
circuit in vitro has been well described. This phenomenon can
change the pharmacokinetic behaviour of drugs during cardiopul-
monary bypass, thus potentially leading to problems in achieving
adequate dosing regimens.
Objective: The aim of this in vitro laboratory study was to compare
the binding of propofol to different oxygenator membranes, and to
examine the effects of the type of prime solution and temperature
on the rate of binding.
Methods: Samples of three types of membrane oxygenators were
used: the SM-35 (polydimethylsiloxane in sheet form), the CML
(polypropylene in sheet form) and the SAFE II (polypropylene in
hollow fibre form). 14C-propofol in either crystalloid solution or
diluted bovine blood was incubated with samples of membranes at
28°C or 37°C. Membrane samples were removed at 30, 60, 90
and 120 min and rinsed. The mass of propofol bound to the
various membranes was then measured using liquid scintillation
counting. This experiment was carried out for both types of prime
solution at 28°C and 37°C.
Results: See Table 1. The SM-35 membrane bound significantly
more propofol than the membranes from the CML and the SAFE II.
Binding of propofol in diluted blood was significantly less than in
crystalloid solution. Temperature had little effect on propofol
binding in either prime solution type.
References
1. Koren G, Crean P, Klein J, Goresky G, Villamater J, MacLeod SM:
Sequestration of fentanyl by the cardiopulmonary bypass
(CPBP). Eur J Clin Pharmacol 1984, 27:51–56.
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sequestration of fentanyl and alfentanil. Br J Anaesth 1986,
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real circuit. J Cardiothorac Anesth 1989, 3(suppl 1):75.
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